46,xx difference of sex development induced by fetoplacental androgens excess

Too much androgen made by the fetus or placenta before birth is the core cause.
It most often stems from congenital adrenal hyperplasia due to a change in the 21-hydroxylase gene, and can also follow placental aromatase deficiency.
Some risks are written in our DNA, passed down through families.
Known risk factors for 46,xx difference of sex development induced by fetoplacental androgens excess include a family history and parents who both carry the same recessive gene change.
Medicines or supplements with androgen effects in pregnancy, and rare fetal or placental tumors that make androgens, can change how strong the features are at birth.

Genetic risk factors

Gene changes in the fetus or the placenta can tilt hormone balance toward androgens before birth, leading to 46,xx difference of sex development induced by fetoplacental androgens excess. In many families, early symptoms of 46,xx difference of sex development induced by fetoplacental androgens excess—like genital differences noticed right after delivery—trace back to inherited variants that raise androgen exposure in the uterus. Most known causes follow an autosomal recessive pattern, where both parents are healthy carriers and each pregnancy has a 1 in 4 (25%) chance to be affected. Risk is not destiny—it varies widely between individuals.

• Aromatase deficiency: Changes in the CYP19A1 gene reduce the placenta’s ability to convert androgens into estrogens, raising fetal androgen levels. This autosomal recessive cause can lead to genital differences in 46,XX newborns and sometimes acne, voice changes, or excess hair in the mother during late pregnancy. Each pregnancy of two carriers has a 25% chance to be affected.

• P450 oxidoreductase: Variants in the POR gene disrupt several steroid-making enzymes, allowing atypical androgen production before birth. In 46,XX fetuses this can cause genital differences, sometimes alongside skeletal features in the baby. Inheritance is autosomal recessive and severity is variable.

• Recessive inheritance: Most genetic causes here are autosomal recessive, meaning a child is affected only after inheriting one changed copy from each parent. Carrier parents are usually healthy. The chance of an affected child is 25% in each pregnancy.

• Parental relatedness: When parents are related by blood, they are more likely to share the same rare gene change. This increases the chance of autosomal recessive conditions such as aromatase or POR deficiency. Genetic counseling and carrier screening can clarify personal risk.

• Family history: Having a sibling or close relative with 46,XX difference of sex development from fetoplacental androgen excess suggests both parents may be carriers. Recurrence risk in future pregnancies is higher than average. Targeted testing in the family helps refine risk estimates.

• Founder variants: Some populations have more common, shared gene changes (founder variants) in genes such as POR or CYP19A1. Knowing ancestry can guide which genes are tested first. A DNA test is still needed to confirm the exact cause.

Transmission

46,xx difference of sex development induced by fetoplacental androgens excess is not contagious and cannot be “caught” from someone else; it develops before birth when the fetus or placenta makes more androgen (male-type) hormones than usual. Most inherited causes follow an autosomal recessive pattern (for example, congenital adrenal hyperplasia or aromatase deficiency); when both parents carry the same nonworking gene, each pregnancy has a 25% (1 in 4) chance to be affected. In other situations, the extra androgens come from non-inherited problems in the fetus or placenta during that pregnancy, so it is not passed down and the chance of it happening again may be low. Because the genetic transmission of 46,xx difference of sex development induced by fetoplacental androgens excess varies by cause, genetic counseling can explain how this condition is inherited in your family and guide testing.

When to test your genes

Consider genetic testing if a newborn with 46,XX has atypical genital development, if prenatal ultrasound or labs suggest excess androgens, or if there is a family history of similar findings or early-onset adrenal issues. Test sooner when cortisol problems are suspected. Results guide sex assignment counseling, monitoring, and tailored care.

Looking ahead can feel daunting, but most children and adults with 46,XX difference of sex development (DSD) induced by fetoplacental androgen excess can live healthy, full lives with attentive care. In medical terms, the long-term outlook is often shaped by both genetics and lifestyle. Survival is typically normal because this form of DSD does not usually affect the heart, lungs, or other vital organs; life expectancy is expected to be similar to the general population when routine health needs are met.

The outlook is not the same for everyone, but most people do well when care teams address the specific drivers of androgen exposure and provide ongoing follow-up. Early symptoms of 46,XX DSD—like genital differences at birth or later signs such as acne, excess hair, or irregular periods—often improve with tailored treatment. Puberty, menstrual health, and fertility may vary; some will have regular cycles and conceive naturally, while others may need hormone management or fertility support. Gender identity is personal; most people with 46,XX DSD raised as girls identify as female, though care should remain affirming and individualized.

Complications to watch for over time include menstrual irregularities, polycystic ovary–like features, and metabolic risks such as insulin resistance, especially if androgen levels remain elevated. Sexual function is usually good, though some may benefit from pelvic floor, hormonal, or surgical support depending on anatomy and comfort. When doctors talk about “remission,” they mean symptoms have eased or disappeared for a while, which can happen if androgen sources are controlled and hormones are balanced. Keep regular appointments—small adjustments can improve long-term health.

Treatment for 46,XX difference of sex development induced by fetoplacental androgen excess focuses on current health needs and long-term well-being, rather than changing chromosomes. Care is usually led by a multidisciplinary team (endocrinology, urology/gynecology, psychology, genetics) and may include hormone management if there are ongoing hormone imbalances, monitoring of growth and puberty, and support for menstrual, sexual, and reproductive health. If genital differences affect urinary function, comfort, or later sexual function, surgery may be considered on a case-by-case basis and ideally timed to align with individual needs and preferences; your doctor can help weigh the pros and cons of each option. Counseling and peer support are important parts of care at any age, and supportive care can make a real difference in how you feel day to day. Not every treatment works the same way for every person, so plans are personalized and reviewed over time to match goals and life stage.

In this subtype, the extra androgens arise from the fetus or placenta, and genes often drive that process. Some conditions are passed down through families (inherited disorders). Doctors may discuss the genetic causes of 46,xx difference of sex development induced by fetoplacental androgens excess, most often congenital adrenal hyperplasia, an autosomal recessive condition in which the fetal adrenal glands cannot make certain hormones efficiently, leading to higher androgen levels before birth. Rarer genetic causes include changes in other hormone-making enzymes or in placental aromatase, the enzyme that normally converts androgens to estrogens. Severity can vary, even among relatives with the same gene change. When a condition is autosomal recessive, each parent typically carries one gene change without symptoms, and with each pregnancy there is a 25% chance (1 in 4) that a child will be affected. Genetic testing can confirm the specific cause, clarify recurrence risk for future pregnancies, and guide care for a newborn with 46,xx difference of sex development induced by fetoplacental androgens excess.

Living with 46,xx difference of sex development induced by fetoplacental androgens excess can intersect with other health issues depending on the underlying cause, which may involve adrenal hormones or low estrogen. Doctors call it a “comorbidity” when two conditions occur together. If the cause is an adrenal enzyme condition, infections, fever, or surgery can strain the body and increase the need for stress-dose steroids, and some medicines for other illnesses may affect how these hormones are managed. When placental or ovarian estrogen is low, there can be added interactions with bone health conditions like osteopenia or osteoporosis, and this may overlap with vitamin D deficiency or limited weight-bearing activity. Over time, some people develop polycystic ovary syndrome–like features, insulin resistance, or high blood pressure, so metabolic conditions can occur alongside the DSD and may influence menstrual patterns, fertility planning, and heart health. Because early symptoms of 46,xx difference of sex development induced by fetoplacental androgens excess often appear at birth, newborn illnesses can complicate evaluation and hormone balance, and later on, mood or anxiety disorders may co-occur, making coordinated care with endocrine, gynecology, mental health, and primary care especially helpful.

How genes can cause diseases

Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.

Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.